![Heiko von der Leyen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Heiko von der Leyen is currently the Medical Director at Orgenesis, Inc. He previously worked as the Managing Director at Hannover Clinical Trial Center GmbH from 2005 to 2017.
Prior to that, he was the Medical Director & VP-Clinical Development at Cardion GmbH from 1998 to 2001.
He also served as the Chief Scientific Officer at Avontec GmbH in 2003 and at Artiss GmbH in 2001-2002.
Postes actifs de Heiko von der Leyen
| Sociétés | Poste | Début |
|---|---|---|
| ORGENESIS INC. | Directeur Technique/Scientifique/R&D | 01/09/2020 |
Anciens postes connus de Heiko von der Leyen
| Sociétés | Poste | Fin |
|---|---|---|
Hannover Clinical Trial Center GmbH | Corporate Officer/Principal | 01/01/2017 |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Directeur Technique/Scientifique/R&D | 01/01/2004 |
Artiss GmbH | Directeur Technique/Scientifique/R&D | 01/01/2002 |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Directeur Technique/Scientifique/R&D | 01/01/2001 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ORGENESIS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Hannover Clinical Trial Center GmbH | |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
Artiss GmbH | |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
